Zobrazeno 1 - 10
of 701
pro vyhledávání: '"Leyland-Jones B"'
Autor:
Hartmaier, R.J. *, *, Trabucco, S.E., Priedigkeit, N., Chung, J.H., Parachoniak, C.A., Vanden Borre, P., Morley, S., Rosenzweig, M., Gay, L.M., Goldberg, M.E., Suh, J., Ali, S.M., Ross, J., Leyland-Jones, B., Young, B., Williams, C., Park, B., Tsai, M., Haley, B., Peguero, J., Callahan, R.D., Sachelarie, I., Cho, J., Atkinson, J.M., Bahreini, A., Nagle, A.M., Puhalla, S.L., Watters, R.J., Erdogan-Yildirim, Z., Cao, L., Oesterreich, S., Mathew, A., Lucas, P.C., Davidson, N.E., Brufsky, A.M., Frampton, G.M., Stephens, P.J., Chmielecki, J., Lee, A.V. *
Publikováno v:
In Annals of Oncology April 2018 29(4):872-880
Autor:
Chung, J.H. *, Pavlick, D., Hartmaier, R., Schrock, A.B., Young, L., Forcier, B., Ye, P., Levin, M.K., Goldberg, M., Burris, H., Gay, L.M., Hoffman, A.D., Stephens, P.J., Frampton, G.M., Lipson, D.M., Nguyen, D.M., Ganesan, S., Park, B.H., Vahdat, L.T., Leyland-Jones, B., Mughal, T.I., Pusztai, L., O’Shaughnessy, J., Miller, V.A., Ross, J.S. *, Ali, S.M.
Publikováno v:
In Annals of Oncology November 2017 28(11):2866-2873
Autor:
Untch, M., Gelber, R.D. *, Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B., de Azambuja, E., Wermuth, P., Khasanov, R., Feng-yi, F., Constantin, C., Mayordomo, J.I., Su, C.-H., Yu, S.-Y., Lluch, A., Senkus-Konefka, E., Price, C., Haslbauer, F., Sahui, T. Suarez, Srimuninnimit, V., Colleoni, M., Coates, A.S., Piccart-Gebhart, M.J., Goldhirsch, A.
Publikováno v:
In Annals of Oncology June 2008 19(6):1090-1096
Autor:
Leyland-Jones, B.
Publikováno v:
In EJC Supplements 2004 2(5):9-12
Autor:
Williams CB, McMahon C, Ali SM, Abramovitz M, Williams KA, Klein J, McKean H, Yelensky R, George Jr TJ, Elvin JA, Soman S, Lipson D, Chmielecki J, Morosini D, Miller VA, Stephens PJ, Ross JS, Leyland-Jones B
Publikováno v:
OncoTargets and Therapy, Vol 2015, Iss default, Pp 3561-3564 (2015)
Casey B Williams,1,* Caitlin McMahon,2,* Siraj M Ali,2 Mark Abramovitz,1 Kirstin A Williams,1 Jessica Klein,1 Heidi McKean,1 Roman Yelensky,2 Thomas J George Jr,3 Julia A Elvin,2 Salil Soman,4 Doron Lipson,2 Juliann Chmielecki,2 Deborah Morosini,2 Vi
Purpose: To assess the prognostic and predictive value of selected biomarkers involved in cell-cycle regulation or proliferation in patients with HER2-positive early breast cancer. Experimental Design: Protein expression of TOP2A, Ki67, cyclin D1, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::2a792644347712708c4fa7c8cab33b09
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086635
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086635
Purpose The Herceptin Adjuvant study is an international multicenter randomized trial that compared 1 or 2 years of trastuzumab given every 3 weeks with observation in women with human epidermal growth factor 2-positive (HER2+) breast cancer after ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::245e0c0b874f57e1a39867c8b42c4ec4
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3087254
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3087254
Autor:
Leyland-Jones, B. *, Arnold, A., Gelmon, K., Verma, S., Ayoub, J.-P., Seidman, A., Dias, R., Howell, J., Rakhit, A.
Publikováno v:
In Annals of Oncology 2001 12 Supplement 1:S43-S47
Autor:
Hiorns, L.R, Seckl, M.J, Paradinas, F, Sharp, S.Y, Skelton, L.A, Brunstrom, G, Newlands, E.S, Kelland, L.R, Leyland-Jones, B *
Publikováno v:
In Journal of Inorganic Biochemistry 1999 77(1):95-104
IMPORTANCE A number of studies suggest that response to antihuman epidermal growth factor receptor-2 (currently known as ERBB2, but referred to as HER2 in this study) agents differs by estrogen receptor (ER) level status. The clinical relevance of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::277a5293f98cd9d62f178f6a9d2a05a7
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3085663
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3085663